Fabtech Technologies FY26 revenue rises 28% to Rs 431 crore
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
Pharma and biotech infrastructure firm targets 25–30% growth as Middle East and Africa emerge as key expansion markets
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Subscribe To Our Newsletter & Stay Updated